AVD

American Vanguard is a genuine turnaround in motion, and the FY2025 numbers show it: gross margin jumped to 28.6% (MD&A: 29% vs. 22% in 2024) as cost of sales fell to 71% of net sales from 78%, inventory reserves normalized ($3.8M vs. $21.4M prior year), operating expenses dropped 21%, and the net loss roughly halved to -$49.9M from -$126M. Deloitte signed an unqualified opinion on both the financials and internal controls, and management argues destocking has 'substantially run its course' — a plausible cyclical-bottom marker. At a $77.3M market cap against $515M of revenue (0.2x P/S), the equity is statistically cheap.

But cheapness here reflects real distress, not a mispriced quality business. This is the second consecutive year of large losses (net margin -9.7%, ROE -25.9%), and revenue is still shrinking — down 6% in 2025 and down for a third straight year from the $610M 2022 peak. Critically, operating cash flow swung to -$21.2M (a 640% deterioration), so the business is consuming cash, not generating it. Against that burn the balance sheet is stretched: long-term debt rose 18% to $174M, average indebtedness held near $195M, and the company paid 'loan amendment origination fees' — language that signals lender renegotiation. Liabilities are 2.10x equity, equity itself fell 17.5%, and the dividend has been cut to zero.